Gossamer Bio (GOSS) Wins $10 Price Target
Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company founded with a mission to develop transformative therapies for…
IO Biotech (IOBT)’s Cancer Vaccine Shows 76% PFS Gain
IO Biotech Inc. (NASDAQ:IOBT) is a clinical-stage biopharmaceutical company pioneering the development of innovative cancer immunotherapies designed to…
Niagen Bioscience (NAGE) Up 503% in 3 Years
Niagen Bioscience, Inc. (NASDAQ:NAGE), formerly known as ChromaDex, is a science-driven company at the forefront of the healthy…
Corvus Pharmaceuticals (CRVS) Net Loss Doubles to $8M in Q2 2025
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, dedicated to pioneering…
Kestra Medical (KMTS) Surges on 52% Revenue Growth
Kestra Medical Technologies Ltd. (NASDAQ:KMTS) is a fast-rising medical technology company specializing in wearable medical devices and digital…
GlucoTrack (GCTK) Posts $9.6M Cash Reserves
GlucoTrack Inc. (NASDAQ:GCTK) is a pioneering medical device company committed to transforming the way diabetes is managed worldwide.…
Adverum (ADVM) Could Soar 460% With $19.75 Target
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a clinical-stage biotechnology company pioneering the development of gene therapies for ocular diseases…
Spero Therapeutics (SPRO) Surges After 200% Stock Jump on Phase 3 Success
Spero Therapeutics, Inc. (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies designed to address some…
Tiziana (TLSA) Surges 143% in 2025
Tiziana Life Sciences Ltd. (NASDAQ:TLSA) is a clinical-stage biotechnology company focused on developing breakthrough immunomodulation therapies designed to…
OKYO Pharma (OKYO) Surges on 75% Pain Reduction in Phase 2 Trial
OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for ophthalmic conditions, with…
Twist Bioscience (TWST) Eyes 46% Upside with $40 Analyst Target
Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company founded in 2013 with a mission to revolutionize the field…
United Therapeutics (UTHR) Tyvaso DPI Sales Hit $315.2M, Up 22% YoY
United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that has become a standout in the pharmaceutical and life…
Instil Bio (TIL) Skyrockets 180% in One Year
Instil Bio Inc. (NASDAQ:TIL) is a biotechnology company that has steadily built its reputation as an innovator in…
Ideaya (IDYA)’s $530M Servier Deal Could Transform Cancer Care
Ideaya Biosciences Inc. (NASDAQ:IDYA) is a precision medicine oncology company that has positioned itself at the forefront of…
Axsome (AXSM) Posts $150M Q2 Revenue, Beats EPS Expectations
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company headquartered in New York City that is focused on…
REGENXBIO (RGNX) Reports $89M Revenue, $6.1M Profit in Q1 2025
REGENXBIO Inc. (NASDAQ:RGNX) is a pioneering biotechnology company based in Rockville, Maryland, focused on harnessing the power of…
Avalo Therapeutics (AVTX) Surges 45% in 6 Months
Avalo Therapeutics Inc. (NASDAQ:AVTX) is a clinical-stage biotechnology company dedicated to developing transformative therapies for immune-mediated and inflammatory…
CERO Stock Price Targets $45—But Reality Sits at $6.93
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) is a clinical-stage biotechnology company based in South San Francisco, California, that is…